minocycline has been researched along with Urticaria* in 5 studies
1 trial(s) available for minocycline and Urticaria
Article | Year |
---|---|
Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris.
In addition to tetracyclines, zinc may constitute an alternative treatment in inflammatory lesions of acne.. To evaluate the place of zinc gluconate in relation to antibiotics in the treatment of acne vulgaris.. Zinc was compared to minocycline in a multicenter randomized double-blind trial. 332 patients received either 30 mg elemental zinc or 100 mg minocycline over 3 months. The primary endpoint was defined as the percentage of the clinical success rate on day 90 (i.e. more than 2/3 decrease in inflammatory lesions, i.e. papules and pustules).. This clinical success rate was 31.2% for zinc and 63.4% for minocycline. Minocycline nevertheless showed a 9% superiority in action at 1 month and one of 17% at 3 months, with respect to the mean change in lesion count. Regarding safety, the majority of the adverse effects of zinc gluconate and of minocycline concerned the gastrointestinal system and were moderate (5 dropouts with zinc gluconate and 4 with minocycline).. Minocycline and zinc gluconate are both effective in the treatment of inflammatory acne, but minocycline has a superior effect evaluated to be 17% in our study. Topics: Abdominal Pain; Acne Vulgaris; Adolescent; Adult; Anti-Bacterial Agents; Arthralgia; Dermatitis, Seborrheic; Double-Blind Method; Female; Gluconates; Humans; Hypersensitivity; Male; Minocycline; Nausea; Patient Compliance; Patient Dropouts; Patient Satisfaction; Skin; Treatment Outcome; Urticaria; Vomiting; Zinc | 2001 |
4 other study(ies) available for minocycline and Urticaria
Article | Year |
---|---|
Symptomatic dermographism induced by oral minocycline: A report of four cases.
Symptomatic dermographism (SD) is the most common form of chronic inducible urticarias. The etiology of this disease has rarely been reported in the literature. Minocycline is widely used in the treatment of acne, rosacea, and other inflammatory skin diseases. Herein we report four cases of SD onset during minocycline administration. These were young women in their 20s to 30s who were taking minocycline orally for acne vulgaris or rosacea. They all experienced the onset of SD 2-3 weeks after taking the drug, and then the complete disappearance of SD 1 month after stopping the drug. Minocycline was thought to be the culprit drug in these cases as other drugs were ruled out on clinical grounds. Our small series suggests that oral minocycline may induce SD, thus raising the awareness of this association in clinical practice. More research is needed to further confirm this association and reveal the underlying mechanism(s). Topics: Acne Vulgaris; Anti-Bacterial Agents; Chronic Inducible Urticaria; Female; Humans; Minocycline; Rosacea; Urticaria | 2023 |
Acute Severe Urticaria From Minocycline.
Topics: Acute Disease; Humans; Minocycline; Urticaria | 2021 |
Unique urticarial presentation of minocycline-induced lupus erythematosus.
The association between guttate psoriasis and infection with group A Streptococcus (GAS) has been well established in the medical literature. However, responses to treatments aimed at GAS eradication such as systemic antibiotics or tonsillectomy are inconsistent. Further complicating treatment recommendations for a disease with a suspected microbial trigger, the standard therapy for severe psoriasis is with systemic immunosuppressant medications. This case report illustrates the role of GAS as a trigger for acute onset severe psoriasis in a child whose skin disease initially worsened with a trial of methotrexate. An immune evaluation confirmed a co-existing selective antibody deficiency. Subsequent treatment with intravenous immune globulin dramatically improved his underlying immune function and decreased GAS infections. This improvement in overall immune function and decrease in GAS infections cleared his skin disease. An interval change in formulation to subcutaneous immune globulin was not as effective. Topics: Adolescent; Anti-Bacterial Agents; Humans; Lupus Erythematosus, Systemic; Male; Minocycline; Urticaria | 2017 |
Minocycline treatment of tetracycline-resistant and tetracycline-responsive acne vulgaris.
The purpose of the study presented herein was to determine the safety and efficacy of minocycline in patients whose acne vulgaris failed to respond adequately to tetracycline therapy and to confirm continued improvement in tetracycline-responsive patients when minocycline was substituted for tetracycline. Thirty-six acne vulgaris patients were given oral tetracycline (250 mg four times a day) for six weeks, followed by oral minocycline (50 mg three times a day) for six weeks. An analysis of the increase or decrease in total lesion counts obtained at biweekly intervals revealed that minocycline caused statically significant improvement both in patients who did not respond to tetracycline and in patients who did respond to tetracycline. Patients who did not respond to tetracycline therapy achieved a mean decrease of 54 percent in lesions after after six weeks of minocycline treatment. In tetracycline-responsive patients, six weeks' treatment with tetracycline caused a 33.5 percent mean decrease in the lesion count. When these patients received minocycline for a subsequent six-week period, the mean lesion count decreased by an additional 60 percent. Only one patient developed a side effect: severe itching and urticaria in a minocycline-treated subject warranted discontinuance of therapy. Minocycline was a safe and effective agent in the treatment of acne both in tetracycline-resistant and in tetracycline-responsive patients. Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Female; Humans; Male; Minocycline; Tetracycline; Tetracyclines; Urticaria | 1981 |